CN119317639A - MHC 1b介导的α-突触核蛋白特异性耐受诱导作为帕金森病的新型治疗方法 - Google Patents

MHC 1b介导的α-突触核蛋白特异性耐受诱导作为帕金森病的新型治疗方法 Download PDF

Info

Publication number
CN119317639A
CN119317639A CN202380029745.8A CN202380029745A CN119317639A CN 119317639 A CN119317639 A CN 119317639A CN 202380029745 A CN202380029745 A CN 202380029745A CN 119317639 A CN119317639 A CN 119317639A
Authority
CN
China
Prior art keywords
seq
domain
amino acid
recombinant polypeptide
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380029745.8A
Other languages
English (en)
Chinese (zh)
Inventor
乔戈·维施胡森
瓦伦汀·布鲁塔尔
叶志宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Julius Maximilians Universitaet Wuerzburg
Original Assignee
Julius Maximilians Universitaet Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Universitaet Wuerzburg filed Critical Julius Maximilians Universitaet Wuerzburg
Publication of CN119317639A publication Critical patent/CN119317639A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202380029745.8A 2022-03-24 2023-03-24 MHC 1b介导的α-突触核蛋白特异性耐受诱导作为帕金森病的新型治疗方法 Pending CN119317639A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22164123.6A EP4249506A1 (en) 2022-03-24 2022-03-24 Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease
EP221641236 2022-03-24
PCT/EP2023/057682 WO2023180548A1 (en) 2022-03-24 2023-03-24 Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease

Publications (1)

Publication Number Publication Date
CN119317639A true CN119317639A (zh) 2025-01-14

Family

ID=81384775

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380029745.8A Pending CN119317639A (zh) 2022-03-24 2023-03-24 MHC 1b介导的α-突触核蛋白特异性耐受诱导作为帕金森病的新型治疗方法

Country Status (12)

Country Link
US (1) US20250205321A1 (https=)
EP (2) EP4249506A1 (https=)
JP (1) JP2025514872A (https=)
KR (1) KR20240162549A (https=)
CN (1) CN119317639A (https=)
AU (1) AU2023238805A1 (https=)
CA (1) CA3250917A1 (https=)
CL (1) CL2024002724A1 (https=)
CO (1) CO2024012329A2 (https=)
IL (1) IL314741A (https=)
MX (1) MX2024011665A (https=)
WO (1) WO2023180548A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024344683A1 (en) * 2023-09-22 2026-04-02 Julius-Maximilians-Universität Würzburg, In Vertretung Des Freistaates Bayern Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630809A1 (en) 2017-05-23 2020-04-08 Bruttel, Valentin Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation

Also Published As

Publication number Publication date
MX2024011665A (es) 2024-09-27
CA3250917A1 (en) 2023-09-28
EP4249506A1 (en) 2023-09-27
CL2024002724A1 (es) 2025-02-14
WO2023180548A1 (en) 2023-09-28
IL314741A (en) 2024-10-01
AU2023238805A1 (en) 2024-07-18
EP4499682A1 (en) 2025-02-05
CO2024012329A2 (es) 2024-09-30
JP2025514872A (ja) 2025-05-12
KR20240162549A (ko) 2024-11-15
US20250205321A1 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
US20220073879A1 (en) Enhanced generation of cytotoxic t-lymphocytes by il-21 mediated foxp3 suppression
JP2019525898A (ja) ヒト白血球抗原拘束ガンマデルタｔ細胞受容体及びその使用方法
JP2000511898A (ja) Ｍｈｃクラスｉｉ抗原提示系及びｃｄ４▲上＋▼ｔ細胞の活性化方法
KR20200113211A (ko) 키메라 항원 수용체를 발현하는 조절 t 세포
KR20190126332A (ko) 암 면역치료요법을 위한 mr1 제한된 t 세포 수용체
JP2013176373A (ja) Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
JP2016539635A (ja) 抗原特異的調節性ｔ細胞の誘導方法
JP2023052033A (ja) 自家ｔ細胞を用いた多発性硬化症の処置方法
KR20210098940A (ko) Ebv 관련 암의 치료를 위한 항-lmp2 tcr-t 세포 요법
JP7606510B2 (ja) Ｅｂｖ－由来抗原に特異的なｔｃｒ構築物
KR20210057750A (ko) 암 면역치료요법을 위한 mr1 제한된 t 세포 수용체
CN114901684A (zh) 粒细胞集落刺激因子受体(g-csfr)的经修饰胞外结构域和结合其的细胞因子
JP5561689B2 (ja) Ｉｌ−１７ｒｂ陽性ｎｋｔ細胞を用いたアレルギー性気道炎症及び／又は気道過敏症の治療薬のスクリーニング方法
CN119317639A (zh) MHC 1b介导的α-突触核蛋白特异性耐受诱导作为帕金森病的新型治疗方法
US6429286B1 (en) Immunoregulatory molecules for costimulatory signal transduction
JP2023536100A (ja) 代替の翻訳開始および翻訳停止に由来する多機能免疫グロブリンフォールドポリペプチド
US20250222083A1 (en) Mhc ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody disease
JP2026502588A (ja) 膜固定サイトカイン、操作された免疫細胞、およびそれらの使用
EP4249062A1 (en) Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
EA052620B1 (ru) ОПОСРЕДОВАННАЯ MHC 1b ИНДУКЦИЯ СПЕЦИФИЧЕСКОЙ ДЛЯ АЛЬФАСИНУКЛЕИНА ТОЛЕРАНТНОСТИ В КАЧЕСТВЕ НОВОГО ЛЕЧЕНИЯ ПРОТИВ БОЛЕЗНИ ПАРКИНСОНА
AU2024344683A1 (en) Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease
WO2020023713A1 (en) Tri-cytokine txm compositions and methods
JP2025527729A (ja) テザリングされたインターロイキン２組み換え受容体及び使用方法
HK40015966A (en) Methods of treating multiple sclerosis using autologous t cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination